Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Fresenius SE & Co (FREA) Stock Price & Analysis

0 Followers

FREA Stock Chart & Stats

€12.80€0.10(0.79%)
At close: 5:30 PM GMT+1
€11€11.5€12Aug 10Sep 4Sep 9Oct 20
Day’s Range
EUR 12.50 - EUR 12.80
52-Week Range
EUR 8.60 - EUR 13.40
Previous Close
EUR 12.70
Volume
N/A
Average Volume (3M)
15
Market Cap
EUR 29.26B
Enterprise Value
EUR 40.41B
Total Cash (Recent Filing)
EUR 1.85B
Total Debt (Recent Filing)
EUR 11.84B
Price to Earnings (P/E)
18.3
Beta
1.04
Next Earnings
Feb 24, 2027 (Est.)
EPS Estimate
0.23
Next Dividend Ex-Date
N/A
Dividend Yield
1.99%

Bulls Say, Bears Say

Bulls Say

Broad-based Growth And Margin Expansion

Broad-based revenue growth and double-digit EBIT expansion indicate improving operating performance across the portfolio rather than reliance on a single business. Higher margins and raised full-year targets strengthen earnings durability and support reinvestment over the next several quarters.

Expanded Biopharma Growth Platform

The expanded biosimilar pipeline and full ownership of mAbxience increase Fresenius's control over development and manufacturing in a strategic growth area. A broader portfolio can support recurring revenue, improve scale, and strengthen the company's long-term biopharma position.

Improved Balance Sheet And Cash Generation

Maintaining leverage within the 2.5x–3x corridor while funding the mAbxience transaction demonstrates meaningful financial discipline. Stronger operating cash generation and lower interest expense provide flexibility to invest, reduce debt, and absorb operational volatility.

Bears Say

Tyenne Supply And Formulary Pressure

Formulary deterioration can reduce access to patients and weaken product economics, while supply constraints prevent Fresenius from fully converting strong demand into revenue. Together, these issues may limit near-term biopharma growth and delay operating leverage.

Nutrition Execution Constraints In China

China-related supply and procurement disruption has already held back Nutrition growth and delayed revenue recognition. Even though management said the supplier issue was resolved, the episode shows that execution challenges can interrupt an otherwise important growth vector.

Higher R&D Burden Ahead

Higher R&D spending should support future products, but it creates a nearer-term burden on margins and cash conversion before those investments generate returns. The increased commitment may therefore temper earnings leverage while multiple pipelines are being developed.

Fresenius SE & Co News

FREA FAQ

What was Fresenius SE & Co’s price range in the past 12 months?
Fresenius SE & Co lowest stock price was €8.60 and its highest was €13.40 in the past 12 months.
What is Fresenius SE & Co’s market cap?
Fresenius SE & Co’s market cap is €29.26B.
When is Fresenius SE & Co’s upcoming earnings report date?
Fresenius SE & Co’s next earnings report is estimated for Feb 24, 2027 (not yet confirmed), which is in 106 days.
How were Fresenius SE & Co’s earnings last quarter?
Fresenius SE & Co released its earnings results on Nov 04, 2026. The company reported €0.181 earnings per share for the quarter, missing the consensus estimate of €0.194 by -€0.013.
Is Fresenius SE & Co overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Fresenius SE & Co pay dividends?
Fresenius SE & Co does not currently pay dividends.
What is Fresenius SE & Co’s EPS estimate?
Fresenius SE & Co’s EPS estimate is 0.23.
How many shares outstanding does Fresenius SE & Co have?
Fresenius SE & Co has 2,252,949,200 shares outstanding.
What happened to Fresenius SE & Co’s price movement after its last earnings report?
Fresenius SE & Co reported an EPS of €0.181 in its last earnings report, missing expectations of €0.194. Following the earnings report the stock price went up 5.882%.
Which hedge fund is a major shareholder of Fresenius SE & Co?
Currently, no hedge funds are holding shares in DE:FREA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology